Healthcare
Poly Medicure Limited (POLYMED) breaks out, gains 5% intraday
Poly Medicure Limited (NSE: POLYMED) stock breaks out of its 6-month resistance trendline, gaining 5% intraday to ₹1651.9.
Poly Medicure Limited (POLYMED) breaks out with a +5% gain to ₹1651.9 on the NSE, clearing its 6M resistance trendline after a period of consolidation. This move is driven by the company’s announcement of an upcoming Investor/Analyst Call/Meet, which likely fueled positive sentiment among investors. Poly Medicure, a key player in the healthcare sector specializing in medical instruments and supplies, has shown resilience and growth potential, making this breakout particularly noteworthy as it may indicate renewed confidence in the company’s future prospects.
Technical setup — trendlines & DMA
From a technical standpoint, Poly Medicure’s current price is well above its 6M support trendline, which ends at ₹1322.87, indicating a robust uptrend. The stock has decisively cleared the 6M resistance trendline at ₹1586.97, signaling a breakout. The 50-DMA at ₹1489.2 is below the 200-DMA at ₹1635.5, typically suggesting a bearish trend, but the recent breakout and strong momentum across various timeframes hint at a potential shift in sentiment. The stock is currently trading in the middle third of its 52W range, which implies there is room for further upside without being overly extended.
Snapshot: ₹1,651.90 on 2026-06-22 (chart frozen at publication)
Fundamentals & business context
On the fundamental front, Poly Medicure’s PE of 49.3, coupled with a profit margin of 17.2% and a robust revenue CAGR of 19.1%, suggests that the market is pricing in significant growth expectations. The company’s consistent revenue growth over the past five years and its excellent profit CAGR of 22.7% indicate strong business quality. Institutional ownership at 21.8% reflects a positive view from smart money, though the absence of a specific NSE catalyst today means the move is likely driven by broader market sentiment and the upcoming investor meet.
Algorithmic scorecard
The overall algorithmic scorecard reflects a balanced view of Poly Medicure, with strong fundamental indicators offset by more cautious technical signals. The company’s revenue and profit CAGRs are particularly strong, indicating solid growth trajectory and business stability. However, the stock’s overvaluation relative to its growth rate and negligible dividend yield are areas of concern. On the positive side, the company’s low debt levels and consistent revenue growth every year highlight its financial health and stability. Conversely, the bearish trend indicated by the DMAs and the stock’s position at a key resistance level suggest that while there is potential for upside, the stock may face near-term resistance.
Company outlook
Poly Medicure’s management has provided a bullish outlook for FY ’27, guiding for consolidated revenue between INR2,300 crores and INR2,400 crores, up from INR1,875 crores in FY ’26. On a standalone basis, the company expects revenue to range from INR1,900 crores to INR1,950 crores, driven by a 20% growth in the domestic business and a 15% growth in the international business. The EBITDA margin is expected to be between 23% and 25% on a consolidated basis and 25% to 27% on a standalone basis. The Renal segment is projected to grow by 20%, while Citieffe is expected to see low double-digit growth in euro terms. The company plans to invest between INR200 crores and INR225 crores in capex, focusing on automation to offset wage revisions and improve margins through synergies and engineering work in India.
Get all details on POLYMED — P&L, peers, shareholding and more on TradeAlone.
FERMENTA
Fermenta Biotech Limited (fermenta) Q2 FY27: Revenue Up 8%, Ebitda Rises 3%
Fermenta Biotech Limited (FERMENTA) reports Q2 FY27 results with revenue up 8% QoQ to INR 135.8 crore and EBITDA up 3% QoQ.
Fermenta Biotech Limited (FERMENTA) announced its financial results for Q2 FY27, showing a robust performance in the quarter. The company reported a revenue of INR 135.8 crore, up 8% from the previous quarter, and EBITDA increased by 3% QoQ to INR 23.2 crore.
Financial Highlights
The consolidated revenue for Q2 FY27 stood at INR 135.8 crore, a marginal increase of 0.1% year-on-year but an 8% rise quarter-over-quarter. The EBITDA for the quarter was INR 23.2 crore, showing a 3% QoQ growth. Profit after tax (PAT) for the quarter was INR 9.4 crore, down 48% YoY but down 1% QoQ.
Sector Performance
Human Nutrition, the primary revenue source, grew by 2% in H1 FY27 to INR 162.5 crore, contributing significantly to the overall revenue. India’s contribution to the half-year revenue rose to 51%, up from 40% a year earlier, reflecting the company’s expanding market presence.
Operational Milestones
Fermenta Biotech Limited achieved several milestones during the quarter, including the FSSAI approval for VITADEE Green® in July, the NSE listing in August, and securing an exclusive license for VIT Vellore Vitamin B12 in September. Looking ahead, the company expects to ramp up VITADEE Green® capacity from Q2 FY28 and aims to complete regulatory approvals for Calcifediol by the end of FY27.
Despite the challenges in the animal nutrition segment, Fermenta Biotech Limited continues to leverage its strengths in human nutrition and diversified markets to drive growth and maintain a low customer concentration, with the largest customer accounting for only 9% of revenue.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Fermenta Biotech Limited
Fermenta Biotech Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Fermenta rises 12.3% over three months, with buying pressure holding steady. Revenue grows at 14.5% CAGR. The company generates cash but does not compound aggressively. The stock holds at 38% of its 52-week range with RSI at 43. In other words, neither side has a clear edge right now. Revenue grows at 14.5% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Fermenta Biotech Limited.
Healthcare
Sai Life Sciences Limited (NSE: Sailife) Q2 FY27: Revenue Growth of 23% Yoy, Sustaining Ebitda Margin
Sai Life Sciences Limited (NSE: SAILIFE) reports Q2 FY27 revenue growth of 23% YoY, maintaining strong EBITDA margin.
Sai Life Sciences Limited (NSE: SAILIFE) announced its financial results for the second quarter and half year ended September 2026, showcasing robust growth and operational efficiency. The company reported a revenue growth of 23% year-on-year (YoY), reaching ₹659 crore for Q2 FY27 compared to ₹537 crore in Q2 FY26. This growth was broad-based, with both Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) sectors delivering healthy performance.
Strong Financial Performance
The EBITDA margin remained stable at 28% for Q2 FY27, reflecting the company’s effective cost management and operational discipline. The company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) stood at ₹187 crore, up 20% YoY. The profit after tax (PAT) also increased by 17% to ₹98 crore. The strong performance was driven by growing traction with global pharmaceutical companies and the increasing adoption of the company’s integrated outsourcing model.
Forward-Looking Outlook
Mr. Krishna Kanumuri, Managing Director and CEO, highlighted the company’s progress in building capacity and capabilities to support long-term customer relationships. The company continues to expect a stronger second half, supported by the progression of its development and commercial pipeline and the ramp-up of new capacity. The capacity and capability expansion program remains on track, with a total of ₹621 crore invested in H1 FY27.
As a result, Sai Life Sciences Limited is well-positioned to capitalize on emerging opportunities in the life sciences industry, maintaining its growth trajectory and delivering value to its stakeholders.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Sai Life Sciences Limited
Sai Life Sciences Limited belongs to the Healthcare › Diagnostics & Research sector. Here’s a quick read on where the business and the stock stand today.
Sai posts a 9.2% three-month gain, but softens in the last few weeks. The PEG of 0.36 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. Revenue grows at 21.3% and profits at 226.9% CAGR. Both numbers are exceptional. RSI stands at 31, well into oversold territory. Yet sellers still dominated on 20 of recent sessions versus 10 for buyers, so the pressure has not fully lifted. Revenue grows at 21.3% and profits at 226.9%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Sai Life Sciences Limited.
ASTRAZEN
Astrazeneca Pharma India Limited Q2 Fy26-27: 30% Growth, INR 7,291 Mn Revenue
AstraZeneca Pharma India Limited reports 30% growth in Q2 FY26-27 with INR 7,291 Mn revenue, driven by strong commercial performance.
AstraZeneca Pharma India Limited (“the Company”), a science-led biopharmaceutical company, announced its second quarter (July 2026 – September 2026) financial results today. The Company reported strong growth of 30% for Q2 FY’26-27, supported by consistent performance across therapy areas it is present in – Oncology, Biopharmaceuticals, and Rare Disease. With that total revenue from operations in H1 2026-27 reaches INR 14,119 Mn growing by 30% from last financial year. This performance reflects disciplined execution, strong operational efficiency, continued portfolio expansion, and increasing adoption of innovative therapies that address unmet patient needs in India.
Financial Performance Summary
The financial performance summary for Q2 2026-27 and H1 2026-27 is as follows:
- Total revenue from Operations: INR 7,291 Mn
- Oncology: INR 5,085 Mn
- Biopharmaceuticals (CVRM, R&I and V&I): INR 1,610 Mn
- Rare Diseases: INR 204 Mn
Key Regulatory Approvals
Three new regulatory approvals in Q2 reinforce our leadership across therapy areas:
- Trastuzumab deruxtecan for HER2-positive Stage II or III early breast cancer
- Trastuzumab deruxtecan for HER2-positive early breast cancer and residual invasive disease
- Trastuzumab deruxtecan in combination with pertuzumab for HER2-positive breast cancer
Strategic Initiatives
AstraZeneca Pharma India Limited has also launched several strategic initiatives:
- MoU with Andhra Pradesh to advance 360-degree Oncology Care Model
- MoU with Telangana to advance AI-enabled lung cancer screening
- K+ Connect – Hyperkalaemia management in Heart Failure and Chronic Kidney Disease
- India Coronary Conquest (ICC) 2026 – Advancing cardiovascular care
Mr. Praveen Rao Akkinepally, Country President & Managing Director, AstraZeneca Pharma India Ltd., said “The continued growth demonstrates the strength of AstraZeneca’s science-led portfolio and our ability to translate innovation into meaningful impact for patients in India. We are accelerating our efforts across oncology, biopharmaceuticals and rare disease. Our focus remains on building strong partnerships across the healthcare ecosystem to bring innovative medicines to more patients faster and improve health outcomes across the country.”
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
AstraZeneca drops 25.6% over three months and trades near its 52-week lows. The PEG reaches 3.73. The stock trades on brand and index weight, not on growth. Thin margins at 7.0% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Sellers drive 1.6x the volume of buyers. Furthermore, they controlled 18 of recent sessions versus 12 for buyers — a clear distribution signal. The business compounds at 31.3% revenue and 23.6% profit CAGR, with D/E of 0.00. Yet the stock drops 25.6% in three months. The business does not deteriorate — the stock does. That gap is what long-term investors look for. Check Fundamentals of AstraZeneca Pharma India Limited.
-
Advertising Agencies2 days agoSignpost India Limited Q2 & H1 FY27 Investor Presentation: Revenue Growth and Profitability on the Rise
-
Consumer Cyclical3 days agoRattanindia Enterprises Limited (rtnindia) Secures Major Order for Revolt Motors’ Electric Motorcycles
-
NUCLEUS2 days agoNucleus Software Exports Limited (nucleus) Partners with Shinhan Finance to Modernize Lending in Vietnam
-
BIOCON2 days agoBiocon Limited Q2 FY27: Revenue Up 2%, Ebitda Margin Declines
-
Consumer Cyclical2 days agoRestaurant Brands Asia Limited (RBA) Launches Avengers: Doomsday Collection
-
Healthcare2 days agoZydus Lifesciences Limited (zyduslife) Q2 FY27: Revenues Surge 29% Yoy
-
Basic Materials2 days agoGrasim Industries Limited (grasim) Partners with Suzlon to Develop Recyclable Wind Turbines
-
Apparel Retail2 days agoV2 Retail Limited (v2retail) Enters Strategic Retail Partnership with Cupid Limited